Physician profile
Benjamin Smith
NPI 1669783668
$2,125.26
in general payments reported to CMS, 2019-2025
19 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $179 · 2021: $235 · 2022: $297 · 2023: $381 · 2024: $422 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $334.65 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $332.23 | 2019-2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $306.84 | 2023-2025 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $242.97 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $220.36 | 2023-2024 | Inpefa |
| Ucb, INC. | $176.30 | 2022-2024 | Briviact, Nayzilam |
| Abbvie INC. | $66.66 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $59.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $58.62 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $55.18 | 2024 | Ultomiris |
| Advanced Respiratory, INC | $41.21 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $40.20 | 2019 | |
| Paratek Pharmaceuticals, INC. | $40.14 | 2023-2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.32 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.71 | 2021-2024 | Watchman Access System |
| Avanir Pharmaceuticals, INC. | $27.76 | 2021-2022 | |
| Vifor Pharma, INC. | $14.63 | 2019 | |
| Melinta Therapeutics, LLC | $14.20 | 2024 | Rezzayo, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.